Literature DB >> 11711694

Diagnosis and management of patients with the antiphospholipid syndrome.

B M Alving1.   

Abstract

The antiphospholipid syndrome is an autoimmune disorder characterized by venous or arterial thrombosis, recurrent pregnancy loss, and thrombocytopenia combined with laboratory tests that indicate the presence of antibodies against phospholipid-binding proteins. The antibodies are directed against a complex of phospholipid with a protein such as beta 2-glycoprotein I (beta 2-GPI) or prothrombin and are detected by means of phospholipid-dependent coagulation assays (known as assays for lupus anticoagulants) and by ELISAs that contain beta 2-GPI and a phospholipid (e.g., cardiolipin). The antiphospholipid syndrome can be associated with other connective tissue disorders such as systemic lupus erythematosus or may be the only manifestation of an autoimmune disorder. Management of patients with this disorder usually includes anticoagulation, which has been found to reduce the rate of recurrence of venous and arterial thrombosis as well as the rate of fetal loss.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11711694     DOI: 10.1023/a:1012798713607

Source DB:  PubMed          Journal:  J Thromb Thrombolysis        ISSN: 0929-5305            Impact factor:   2.300


  23 in total

Review 1.  Antiphospholipid antibodies and thrombosis.

Authors:  M Greaves
Journal:  Lancet       Date:  1999-04-17       Impact factor: 79.321

Review 2.  Criteria for antiphospholipid syndrome: early pregnancy loss, fetal loss, or recurrent pregnancy loss?

Authors:  D W Branch; R M Silver
Journal:  Lupus       Date:  1996-10       Impact factor: 2.911

3.  The catastrophic antiphospholipid syndrome 1996: acute multi-organ failure associated with antiphospholipid antibodies: a review of 31 patients.

Authors:  R A Asherson; J C Piette
Journal:  Lupus       Date:  1996-10       Impact factor: 2.911

Review 4.  Antiphospholipid antibodies: anticardiolipin and the lupus anticoagulant in systemic lupus erythematosus (SLE) and in non-SLE disorders. Prevalence and clinical significance.

Authors:  P E Love; S A Santoro
Journal:  Ann Intern Med       Date:  1990-05-01       Impact factor: 25.391

5.  Anticardiolipin antibodies in autoimmune thrombocytopenic purpura.

Authors:  E N Harris; A E Gharavi; U Hegde; G Derue; S H Morgan; H Englert; J K Chan; R A Asherson; G R Hughes
Journal:  Br J Haematol       Date:  1985-02       Impact factor: 6.998

Review 6.  Safety of low-molecular-weight heparin in pregnancy: a systematic review.

Authors:  B J Sanson; A W Lensing; M H Prins; J S Ginsberg; Z S Barkagan; E Lavenne-Pardonge; B Brenner; M Dulitzky; J D Nielsen; Z Boda; S Turi; M R Mac Gillavry; K Hamulyák; I M Theunissen; B J Hunt; H R Büller
Journal:  Thromb Haemost       Date:  1999-05       Impact factor: 5.249

7.  Cerebrovascular and neurologic disease associated with antiphospholipid antibodies: 48 cases.

Authors:  S R Levine; M J Deegan; N Futrell; K M Welch
Journal:  Neurology       Date:  1990-08       Impact factor: 9.910

Review 8.  Antiphospholipid antibody-mediated disruption of the annexin-V antithrombotic shield: a thrombogenic mechanism for the antiphospholipid syndrome.

Authors:  J H Rand
Journal:  J Autoimmun       Date:  2000-09       Impact factor: 7.094

9.  Randomised controlled trial of aspirin and aspirin plus heparin in pregnant women with recurrent miscarriage associated with phospholipid antibodies (or antiphospholipid antibodies)

Authors:  R Rai; H Cohen; M Dave; L Regan
Journal:  BMJ       Date:  1997-01-25

10.  Thrombocytopenia in SLE and related autoimmune disorders: association with anticardiolipin antibody.

Authors:  E N Harris; R A Asherson; A E Gharavi; S H Morgan; G Derue; G R Hughes
Journal:  Br J Haematol       Date:  1985-02       Impact factor: 6.998

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.